PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Patentee’s own post-published data undermines the credibility of their broad cat antibody patent (T 0709/23)

  • Technology: Patent law, Pharmaceuticals
  • 27th October 2025
How early is too early to file a biotech patent? EPO decision T 0709/23 provides a costly answer, demonstrating the fatal risks of claiming a broad therapeutic use before the link between structure, function, and actual effect is truly understood.
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image

Originally posted on IPKat.

The decision in T 0709/23, relating to a broadly claimed antibody invention, neatly illustrates the pitfalls of filing for a biotech invention too early before the link between structure, function and therapeutic effect has been sufficiently elucidated. Interestingly, this is also another example of a case in which post-published evidence from the patentee themselves undermined the original application, rendering it insufficiently disclosed over the whole scope of the claim.

EPO standards for sufficiency: Credibility of therapeutic effect (Article 83 EPC & G2/21)

For therapeutic inventions relating to the medical use of a substance or composition, therefore, the case law interprets the disclosure and sufficiency requirement of Article 83 EPC as requiring the claim to satisfy two tests. First, the skilled person must be able to make the substance or composition without undue burden. Second, it must be credible/plausible that the substance or composition actually achieves the claimed therapeutic effect. Importantly, in most cases, for the requirement of sufficiency to be met, the patent application must provide suitable evidence for the claimed therapeutic use. A mere assertion of a therapeutic effect is not enough. Instead, the application as filed must provide a credible basis for the claim. 

As the EBA confirmed in G2/21 “it is necessary that the patent at the date of its filing renders it credible that the [a] therapeutic agent, i.e. the product, is suitable for the claimed therapeutic application” (G2/21, r.74). According to the Board of Appeal interpretations of G2/21, post-published evidence may also be used to support a technical effect that was made credible by the application as filed. 

Case T 0709/23: A broad functional claim supported by interspecies data

The patent in question in this case was EP3219729 owned by Zoetis Services and directed to an antibody for treating pruritic (itchy) and allergic conditions in cats. The claims defined the antibody purely by its function in inhibiting the inflammatory cytokine IL-31. The granted claims were impressively broad, with claim 1 reading simply:

An isolated antibody that specifically binds to feline IL-31, wherein said antibody reduces, inhibits or neutralizes feline IL-31-mediated pSTAT signaling in a cell based assay.

The claims of the Main Request on appeal were amended to also specify:

…for use in treating a pruritic condition or an allergic condition in cats.

The patent application provided data  demonstrating that example antibodies were effective at reducing itch in dogs. Based on the genetic similarity between canine and feline IL-31, the Patentee argued that it was credible these antibodies would also work in cats. The Patentee further supported their argument by pointing to documents showing that some medications for atopic dermatitis are used in both dogs and cats. The Opponents, including Boehringer Ingelheim Vetmedica GmbH, argued in response that the extrapolation from dogs to cats was speculative and that the patent failed to provide a sufficient disclosure for the claimed use in cats.

Post-published evidence contradicts the invention

Interestingly, the Board of Appeal decided that it was not necessary to settle the dog versus cat debate. Instead the Board of Appeal based its sufficiency assessment on the broader question of whether the invention could be carried out over its entire scope without undue burden. The Board of Appeal proceeded by simply assuming that the therapeutic effect observed in dogs was also credibly achieved in cats, allowing it to move on to what it considered was the more critical issue of whether the claim as a whole was credible. 

As interpreted by the Board of Appeal, the patent’s central teaching was that antibodies binding a specific, conserved region on IL-31 would be effective at treating itching in cats. The application as filed particularly suggested that the antibodies binding this epitope would block the interaction of IL-31 with its receptor. This hypothesis was based on the functional effects observed with respect to an exemplary antibody “11E12” at inhibiting IL-31-mediated pSTAT signalling. 

This is where post-published evidence became relevant. The Patentee submitted post-published evidence describing detailed later experiments. These data showed that whilst the example 11E12 antibody did indeed inhibit pSTAT signalling as required by the claim, it completely failed to reduce itch in cats in a real-world study. However, the post-published document also contained data for a different antibody 15H05, which did reduce itching in cats. Importantly, however, the 15H05 antibody worked by binding to a completely different and previously unknown epitope on IL-31 than the 11E12 antibody. 

Unfortunately for the Patentee, the Board of Appeal considered the post-published evidence as detrimental to the Patentee’s case. For the Board of Appeal, the post-published results demonstrated “that there is no clear correlation between the functional features of reducing, inhibiting or neutralising feline IL-31-mediated pSTAT signalling in a cell-based assay” and a therapeutic effect of reducing itching in cats (r.13). The example antibody which was shown to have the cited functional features was subsequently shown to lack any therapeutic effect. 

The Board of Appeal also noted that the patent application as originally filed did not suggest that a skilled person should look for antibodies having a different IL-31 epitope to the antibody used in the examples. The Board of Appeal therefore concluded that the patent’s teaching would not have been much help to a skilled person. For the Board of Appeal, to perform the invention, the skilled person would have had to embark on a new research programme to identify an entirely new epitope, which would constitute an undue burden for the skilled person. The appeal was therefore dismissed and the patent was revoked for insufficiency.

Analysis

This case is the second recent case to fall down based on harmful post-published data originating from the patentee themselves. This decision also demonstrates the limits of functional claiming at the EPO. Whilst the EPO is more permissive than the US when it comes to broad, functionally-defined antibody claims, this case shows us that the disclosure in Europe must still provide a reliable and repeatable path to success across the entire scope claimed. When using functional claim language it is therefore very important to link the specified function, and supporting data, with the actual problem solved by the invention. In this case, the Board of Appeal identified a disconnect between the functional language, the data provided in the application as filed, and the claimed therapeutic effect. 

In the antibody field, the decision contrasts with cases like T 0326/22 and T 0835/21, in which broad functional claims were upheld because the patent provided adequate guidance to obtain antibodies with the claimed properties. Unlike T 0435/20, in which insufficiency arose from the inherent difficulty of making antibodies to a complex conformational epitope without proper guidance, the problem in T 0709/23 was that the guidance on epitope selection provided in the application as filed was actively misleading as the post-published evidence suggested that a different epitope was needed. Indeed, the new epitope identified in the post-published evidence may be considered its own invention. 

On closer investigation, it turns out that the post-published data submitted in the present case was in fact taken from a later patent application filed by the Patentee (WO 2019177697 A2), claiming the new epitope, filed 7 years later. Unsurprisingly, the earlier case is cited as prior art on the later case. This case therefore neatly illustrates the dangers of filing a patent for a broad antibody invention too early, before the link between structure, function and invention was fully elucidated. This strategy runs the risk of revocation for insufficiency whilst simultaneously scuppering future filings to the clinical lead. 

Author: Rose Hughes

Rose Hughes

Rose is driven by a passion for science and combining scientific knowledge with practical IP solutions. Rose brings over a decade of pharmaceutical and biotech patent expertise to Evolve, including both law firm experience and six years working in-house at AstraZeneca. Rose’s passion for science stems back to her PhD in immunology and infectious disease at UCL, working on the innate immune responses of macrophages to viral infection.

At AstraZeneca, Rose led IP strategy for products at every stage of the pipeline, including on-market assets. She was responsible for developing and executing the IP strategy for the biopharma cell therapy department and the neuroscience division. Rose has also completed due diligence and negotiated IP terms for high-profile transactions in the biopharma and oncology space, including cell therapy platform deals. Rose provides invaluable industry expertise to address the unique challenges of IP strategy in the life sciences sector.

Related insights...

Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

Not just synergy: Other ways to support a drug combo invention (T 0593/24)

  • 17th November 2026
It is often necessary to support a drug combination invention with synergy data. This can be a problem for innovators, given that synergy data may not be assessed in the clinic, as additive effects may be sufficient for regulatory approval. However, T 0593/24 is a reminder that, if you lack synergy data, this may not…
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

Fractional IP counsel for biotech: what to look for in a fractional IP adviser

  • 16th November 2026
What to look for in part-time senior IP support for a growing biotech, from Series A to partnering and acquisition, and how experienced fractional IP counsel can help at every stage.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Post-published clinical data does not always save you (T 0251/25, Empagliflozin)

  • 3rd November 2026
Empagliflozin (Jardiance) is approved in the US for reducing the risk of cardiovascular death in adults with type 2 diabetes (T2D) and established cardiovascular disease, and in Europe for reducing the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure. The recent decision in T 0251/25 nonetheless found Boehringer Ingelheim’s…
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Reformatio in peius survives a procedural violation (T 1168/24)

  • 2nd November 2026
Sometimes patent law is about procedures and not inventions. The appeal in T 1168/24 related to the lipid nanoparticle (LNP) technology behind the COVID-19 vaccines, opposed by Merck and Moderna. After two rounds of opposition and two appeals, the patent was revoked for added matter. Whilst the global litigation surrounding LNPs is interesting in its…
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)

  • 6th October 2026
The Federal Circuit’s decision in Wyeth v AstraZeneca (No. 2024-2325) applied the enablement test to a dose invention. The case is an interesting contrast to the other recent case to apply enablement to a method of treatment claim, Teva v Eli Lilly.
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image

Lack of clarity by the backdoor: An ambiguity “may simply result in a broader interpretation” (T 0977/25)

  • 4th October 2026
In T 0977/25, a Board of Appeal found that the word “it” in an amended method claim for an e-cigarette cartridge was ambiguous.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

G1/25: What are the consequences?

  • 12th September 2026
Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

BREAKING: When real doubt hits – G1/25 changes the description adaptation requirement for the worse

  • 4th September 2026
G 1/25, issued today, holds that the description must be adapted only where an “inconsistency” between the claims and description causes non-compliance with another requirement of the EPC.
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26)

  • 23rd July 2026
We now have confirmation of a new referral to the EBA on claim interpretation (G1/26). As previously hinted, the Board of Appeal in T 0873/24 has decided to refer questions on the application of G1/24 to the assessment of added matter.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

When do you file for a drug combination invention? (T 592/24)

  • 16th July 2026
Drug combination inventions are increasingly difficult to protect. File too early for a drug-combination invention and the application may lack the data to support the non-obvious effect of the combination. Wait for the trial read-out, and a competitor, or your own published protocol, may have already placed the invention in the public domain. 
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice